DXCM monthly performance report
Check DXCM's monthly returns, drawdown, and seasonality trends — updated every month.
DXCM monthly report
—
Key takeaways
- Dexcom (DXCM) closed November 2026 at $81.39, down 1.09% for the month and +36.54% over the trailing 12 months.
- Year-to-date, DXCM is +22.63%, outperforming the S&P 500 which has returned +11.03% YTD.
- The stock is trading +8.46% versus its 200-day moving average ($75.04), a bullish technical signal.
- Over the past three years, DXCM has underperformed the S&P 500 by −85.30%, with a relative strength index reading of 48.1.
- Win rate over the trailing 39 months stands at 46.2% — 18 positive months versus 21 negative months.
Dexcom ended November 2026 at $81.39, posting a monthly return of −1.09%. The S&P 500 returned +0.19% over the same window, leaving relative performance at −1.28%.
The current quarter stands at −5.68% (Q4 2026 (QTD)), while medium-term trend remains constructive: price is +8.46% versus the 200-day moving average ($75.04).
Year-to-date, DXCM is +22.63% against SPY +11.03%, a gap of +11.60%. The stock is currently −12.10% below its 52-week high, with maximum 3-year drawdown at −60.95%.
| Period | DXCM | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +1.29% | −0.35% | +1.65% |
| 1 Week | −3.63% | +3.29% | −6.93% |
| 1 Month | −1.09% | +0.19% | −1.28% |
| 3 Months | −9.31% | −2.48% | −6.84% |
| 6 Months | +38.96% | +2.00% | +36.97% |
| YTD | +22.63% | +11.03% | +11.60% |
| 12 Months | +36.54% | +10.79% | +25.75% |
| 3 Years | −13.46% | +71.83% | −85.30% |
| Rank | Month | Return |
|---|---|---|
| #1 | Nov 2023 | +30.05% |
| #2 | Jul 2026 | +23.90% |
| #3 | May 2026 | +23.83% |
| #4 | Mar 2024 | +20.54% |
| #5 | May 2025 | +20.20% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jul 2024 | −40.18% |
| #2 | Mar 2025 | −22.72% |
| #3 | Mar 2026 | −14.48% |
| #4 | Oct 2025 | −13.48% |
| #5 | Sep 2025 | −10.68% |
| Quarter | Return |
|---|---|
| Q3 2025 | −22.91% |
| Q4 2025 | −1.37% |
| Q1 2026 | −5.38% |
| Q2 2026 | +7.25% |
| Q3 2026 | +28.12% |
| Q4 2026 (QTD) | −5.68% |
| Year | Return |
|---|---|
| 2023 | +9.58% |
| 2024 | −37.33% |
| 2025 | −14.66% |
| 2026 | +22.63% |
| Metric | Value |
|---|---|
| 52-Week High | $92.59 (2026-08-24) |
| 52-Week Low | $55.84 (2025-11-11) |
| Current Price | $81.39 |
| 200-Day Moving Average | $75.04 |
| Price vs 200DMA | +8.46% |
| 3-Year Maximum Drawdown | −60.95% (2025-11-10) |
| Current Drawdown from 52W High | −12.10% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 48.1 |
| 3-Year Excess Return vs S&P 500 | −85.30% |
| RS Peak | 122.7 (Apr 2024) |
| RS Trough | 34.6 (May 2026) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was DXCM's return for this report period?
DXCM returned −1.09% in the latest monthly window ending 2026-11-12.
Has DXCM outperformed SPY year to date?
YTD DXCM: +22.63% vs SPY: +11.03%.
What is DXCM's 12-month return?
+36.54% over the trailing 12 months.
Is DXCM above or below its 200-day moving average?
Price is +8.46% versus 200DMA ($75.04).
What is the maximum drawdown in the 3-year window?
−60.95% on 2025-11-10.